MedTrace Logo

A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers

NCT00736606 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-12-02

No results posted yet for this study

Summary

The purpose of the study is to assess the pharmacokinetics of both AZD9056 (steady state) and simvastatin (single dose) when co-administered in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

simvastatin

One single dose of 40mg

DRUG

AZD9056 + simvastatin

AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7

Sponsors & Collaborators

Principal Investigators

  • Rod Hepburn · AstraZeneca R&D, Charnwood, UK

  • Maura Fallon · PAREXEL Clinical Pharmacology Research Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736606 on ClinicalTrials.gov